{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:58Z","timestamp":1793059078655,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.08.016","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:02:01Z","timestamp":1788879721000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonists in dermatology: ethical considerations"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9997-1902","authenticated-orcid":false,"given":"Chelsea","family":"Deitelzweig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1564-2325","authenticated-orcid":false,"given":"Fatima","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K","family":"Stoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.08.016_bib0001","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(09)60137-9","article-title":"Principles for allocation of scarce medical interventions","volume":"373","author":"Persad","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0003","article-title":"Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"34","author":"Rodriguez","year":"2024","journal-title":"Lancet Reg Health Am."},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0004","first-page":"qxag130","article-title":"Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings","volume":"4","author":"Stein","year":"2026","journal-title":"Health Aff Sch"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025545","article-title":"Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States","volume":"11","author":"Lu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55222","article-title":"Factors associated with semaglutide initiation among adults with obesity","volume":"8","author":"Podolsky","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DHPS.S496619","article-title":"Comparing out-of-pocket costs and health-related quality of life between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes","volume":"17","author":"Hu","year":"2025","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0008","unstructured":"Centers for Medicare and Medicaid Services. Medicare GLP-1 bridge. Available at: https:\/\/www.cms.gov\/medicare\/coverage\/prescription-drug-coverage\/medicare-glp-1-bridge. Accessed August 8, 2026."},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0009","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s11606-025-10026-6","article-title":"Ethical considerations in the use of weight loss medications","volume":"41","author":"Savla","year":"2026","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/intqhc\/mzaf131","article-title":"Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform","volume":"38","author":"Vaidya","year":"2026","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0011","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jval.2024.03.991","article-title":"EPH163 off-label use of semaglutide in the United States: increasing prevalence, variability in prescribing provider specialty, and patient characteristics","volume":"27","author":"Noxon","year":"2024","journal-title":"Value in Health"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2025.100100","article-title":"Health disparity clusters of off label prescriptions for glucagon-like peptide 1 receptor agonists","volume":"13","author":"Spinelli","year":"2025","journal-title":"Am J Med Open"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharma3040025","article-title":"The inappropriate use of GLP-1 analogs: reflections from pharmacoepidemiology","volume":"3","author":"Echeverry-Guerrero","year":"2024","journal-title":"Pharmacoepidemiology"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0014","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bioe.70068","article-title":"Ethical issues related to the use of GLP-1 receptor agonists such as Ozempic and Mounjaro: impact on individuals and society at large","volume":"40","author":"Minerva","year":"2026","journal-title":"Bioethics"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0015","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMp2400978","article-title":"Fair allocation of GLP-1 and dual GLP-1\u2013GIP receptor agonists","volume":"390","author":"Emanuel","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.5015","article-title":"Marketing and safety concerns for compounded GLP-1 receptor agonists","volume":"6","author":"Mattingly","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2026.2207","article-title":"Postshortage compounded GLP-1 RA market in 2 states with potentially high demand","volume":"7","author":"DiStefano","year":"2026","journal-title":"JAMA Health Forum"},{"issue":"8 Suppl 1","key":"10.1016\/j.clindermatol.2026.08.016_bib0018","first-page":"S23","article-title":"Clinical and legal considerations in pharmaceutical compounding","volume":"16","author":"Kircik","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0019","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14740338.2025.2499670","article-title":"Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system","volume":"25","author":"McCall","year":"2026","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0020","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s11095-024-03771-6","article-title":"Impact of manufacturing process and compounding on properties and quality of follow-on GLP-1 polypeptide drugs","volume":"41","author":"Hach","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0021","unstructured":"American Diabetes Association. The American Diabetes Association Announces Statement on Compounded Incretin Products. American Diabetes Association. Available at: https:\/\/diabetes.org\/newsroom\/press-releases\/american-diabetes-association-announces-statement-compounded-incretin. Accessed August 8, 2026."},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0022","unstructured":"United States Food and Drug Administration. FDA intends to take action against non-FDA-approved GLP-1 drugs. February 6, 2026. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-intends-take-action-against-non-fda-approved-glp-1-drugs. Accessed August 8, 2026."},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jme-2024-110374","article-title":"The ethics of Ozempic and Wegovy","volume":"52","author":"Ryan","year":"2026","journal-title":"J Med Ethics"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2026.103082","article-title":"TikTokfluence: the rise of GLP-1 receptor agonists in the age of social media health trends","volume":"66","author":"G\u00fcnaltay","year":"2026","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0025","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1097\/MS9.0000000000003801","article-title":"From prescription to trend: the misuse of Ozempic in the age of social media","volume":"87","author":"Muhammad","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0026","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00210-025-04403-5","article-title":"Misrepresentation of semaglutide in social media","volume":"399","author":"Propfe","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0027","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/asj\/sjad211","article-title":"Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: a Google trends analysis","volume":"44","author":"Han","year":"2023","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0028","article-title":"Navigating digital dermatology: an analysis of acne-related content on TikTok","volume":"15","author":"Irfan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0029","first-page":"42","article-title":"A review of glucagon-like peptide-1 in dermatology","volume":"18","author":"Patino","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0030","first-page":"1026","article-title":"GLP-1 receptor agonists for the dermatologist: uses and considerations","volume":"23","author":"Vidal","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0031","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","article-title":"Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa","volume":"161","author":"Gouvrion","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0032","doi-asserted-by":"crossref","first-page":"869","DOI":"10.36849\/JDD.8926","article-title":"Glucagon-like peptide-1 Receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa: a multicenter TriNetX Cohort Study","volume":"24","author":"Gupta","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0033","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamadermatol.2026.1907","article-title":"GLP-1 receptor agonist use and clinical outcomes in patients with hidradenitis suppurativa","volume":"162","author":"Jastrz\u0105b-Mi\u015bkiewicz","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0034","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ced\/llag025","article-title":"Expanding the dermatological horizon of glucagon-like peptide-1 receptor agonists: response to 'Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study'","volume":"51","author":"Potluru","year":"2026","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0035","first-page":"1148","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis","volume":"22","author":"Ku","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0036","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamadermatol.2026.1753","article-title":"Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial","volume":"162","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0037","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: a review","volume":"162","author":"Sheth","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0038","unstructured":"AMA Ed Hub. Weight Management Implications Applying Medications such as GLP-1s. Available at: https:\/\/edhub.ama-assn.org\/pages\/weight-management-glp1. Accessed July 12, 2026."},{"key":"10.1016\/j.clindermatol.2026.08.016_bib0039","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:32:46Z","timestamp":1790890366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0738081X26002270"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.08.016","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists in dermatology: ethical considerations","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}